HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

DERM

Journey Medical Corporation (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Strong Buy 1.0 / 5 4 analysts
$7.04
$-0.04 (-0.56%)
Target: $13.50 (91.8%)
Sign in to add DERM to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$193.84M
P/E Ratio (TTM)-
Forward P/E-117.33
EPS (TTM)$-0.37
Dividend Yield-
Profit Margin-14.82%
Revenue Growth21.50%
ROE-36.62%
Debt/Equity82.60
Recommendation Strong Buy 1.0
Analyst Target$13.50
Analysts4
Indexes NASDAQ

Technical Indicators

RSI (14)65.4
Beta1.10
SMA 20-
SMA 40-
52-Week High$9.56
52-Week Low$4.31
50-Day Avg$5.89
200-Day Avg$7.11
Avg Volume275.1K
Volume155.6K

Performance Analysis

BULLISH

DERM shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 52% of its 52-week range.
+ RSI at 65.4 shows positive momentum.
+ Strong revenue growth of 21.5% year-over-year.
- Operating at a loss with -14.8% margin.
+ Wall Street consensus is "Strong Buy" from 4 analysts.
+ Average analyst target of $13.50 implies 91.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:05 UTC

Back to Screener Export Report